Marker Therapeutics (MRKR) announced the appointment of Kathryn Penkus Corzo, R.Ph., MBA to the Company’s Board of Directors, effective November 1, 2025. Most recently, Penkus Corzo served as President and Chief Operating Officer at bit.bio.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRKR:
- Marker Therapeutics’ Innovative Approach in AML and MDS Treatment: A Study Update
- Marker Therapeutics’ MT-601 Study: A Promising Step in Lymphoma Treatment
- Marker Therapeutics Advances Off-the-Shelf T Cell Therapy with First Patient Treatment
- Marker Therapeutics announces first patient treated in off-the-shelf program